Tamiflu: la nouvelle controverse
ROCHE. Deux articles à paraître aujourd’hui dans la presse médicale internationale dénoncent la stratégie et la communication...
Eric Schaerlig
- ABB LTD N44.97-0.18%
- ALCON N80.30.93%
- RICHEMONT N145.80.69%
- GEBERIT N587.20.24%
- GIVAUDAN N40110.3%
- HOLCIM N94.440.45%
- KUEHNE+NAGEL INT N178.05-3.13%
- LOGITECH N672.07%
- LONZA N588.22.98%
- NESTLE N87.50.51%
- NOVARTIS N90.84-0.3%
- PARTNERS GROUP N11131.32%
- ROCHE GS257.8-0.81%
- SIKA N2070.34%
- SONOVA HOLDING AG260.12.6%
- SWISS LIFE HOLDING AG N840.40.07%
- SWISS RE N149.850.47%
- SWISSCOM N542.50.46%
- UBS GROUP N26.031.01%
- ZURICH INSURANCE N578-0.86%
- ABB LTD N44.97-0.18%
- ALCON N80.30.93%
- RICHEMONT N145.80.69%
- GEBERIT N587.20.24%
- GIVAUDAN N40110.3%
- HOLCIM N94.440.45%
- KUEHNE+NAGEL INT N178.05-3.13%
- LOGITECH N672.07%
- LONZA N588.22.98%
- NESTLE N87.50.51%
- NOVARTIS N90.84-0.3%
- PARTNERS GROUP N11131.32%
- ROCHE GS257.8-0.81%
- SIKA N2070.34%
- SONOVA HOLDING AG260.12.6%
- SWISS LIFE HOLDING AG N840.40.07%
- SWISS RE N149.850.47%
- SWISSCOM N542.50.46%
- UBS GROUP N26.031.01%
- ZURICH INSURANCE N578-0.86%